|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||35.60 - 35.76|
|52-week range||27.26 - 40.43|
|PE ratio (TTM)||18.14|
|Forward dividend & yield||0.62 (1.62%)|
|1y target est||39.92|
Smith & Nephew shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Smith & Nephew shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
It is unclear how much stake the activist investor owns or what it plans to push for at the company, according to the Bloomberg report. "We do not comment on rumour or speculation and we do not comment on the identity of our investors other than those publicly disclosed," Smith & Nephew said in an emailed statement. Elliott declined to comment.
Billionaire Paul Singer’s hedge fund Elliott Management Corp. has built a stake in Smith & Nephew Plc, the maker of artificial hips and knees, according to people familiar with the matter.
Zeroing in on dividend stocks with a solid Zacks Rank is a great way to increase the chances of beating volatile market conditions while ensuring a steady stream of cash flow. Here are three top picks in the MedTech space.
Artificial hip and knee maker Smith & Nephew (Frankfurt: 502816 - news) reported a 3 percent rise in underlying revenue growth in the second quarter, in line with its 3-4 percent forecast for the year, helped by 13 percent growth in emerging markets. Chief Executive Olivier Bohuon said on Thursday the company was seeing good momentum, keeping it on track to deliver on full year revenue and trading margin guidance. Smith & Nephew, which competes against larger U.S. rivals in the orthopaedic replacement market, is battling to bring new technology on-stream to help it win business, with robotics a key area of innovation.
The world's top medical technology companies are turning to robots to help with complex knee surgery, promising quicker procedures and better results in operations that often leave patients dissatisfied. Demand for artificial replacement joints is growing fast, as baby boomers' knees and hips wear out, but for the past 15 years rival firms have failed to deliver a technological advance to gain them significant market share.
LONDON--(BUSINESSWIRE)-- Smith & Nephew (LSE:SN)(NYSE:SNN), the global medical technology business, proudly supports results of an independent, randomised clinical trial 1 concluding that, in the patients ...
Shares in Smith & Nephew (Frankfurt: 502816 - news) rose to a nine-month high on Friday after the artificial hip and knee maker said a strong first quarter, led by growth in emerging markets, put it on track to meet it targets for the year. The company reported underlying revenue growth of 3 percent, within the 3-4 percent range it has forecast for the year, in what analysts said was likely to be its weakest quarter. Chief Executive Olivier Bohuon said the company had made a good start to the year, highlighting emerging markets, where growth returned to double-digits, with China up by an underlying 14 percent.
The chief executive of Smith & Nephew said on Friday that M&A was not at the top of his agenda, as the focus was on driving growth at the artificial knee and hip maker. A report in the Financial Times in March said Wright Medical , a U.S. company that specialise in surgical implants for extremities like feet and ankles, could be a takeover target for the British company. S&N Chief Executive Olivier Bohuon said M&A was "always on the agenda", and he had previously pointed to extremities as one of a number of areas of interest.
Smith & Nephew, Europe's biggest artificial hip and knee maker, reported a 3 percent rise in underlying revenue in its first quarter, helped by a return to double-digit growth in emerging markets and a ...
Smith & Nephew (Frankfurt: 502816 - news) , Europe's biggest manufacturer of artificial hips and knees, reported a 7 percent drop in full-year trading profit, missing analysts' forecasts, as tough conditions in China and Saudi Arabia kept growth in check. Smith & Nephew reported trading profit of $1.02 billion on revenue up 2 percent on an underlying basis at $4.67 billion.
Britain's top share index steadied on Thursday as falls among mining stocks weighed, while Smith & Nephew dropped after posting disappointing results. The blue chip FTSE 100 index was up 0.1 percent at 7,192.70 points by 1028 GMT, underperforming the broader European market. Artificial hip and knee maker Smith & Nephew booked a 7 percent drop in full-year trading profit, missing analysts' forecasts, hit by difficult market conditions in China and Saudi Arabia.
** Artificial joint maker Smith & Nephew falls 4.3 pct, bottom of the FTSE 100, after FY profits fell 7 pct ** Co cites weakness in China for fall ** Revenues miss analyst estimates , profit also lower ...
Oct.11 -- Activist investor Paul Singer is honing in on Europe, building stakes in an engineering and healthcare company. An after hour statement revealed Singer's hedge fund Elliott Management added German engineering firm GEA to its portfolio and according to people familiar with the matter, it also took a stake in the British company Smith & Nephew. Bloomberg's Ruth David reports on "Bloomberg Markets: European Open."